NEURALSTEM INC (CUR) Stock Price & Overview
NYSEARCA:CUR • US64127R3021
Current stock price
The current stock price of CUR is 1.52 null. Today CUR is down by -16.94%. In the past month the price increased by 4.83%. In the past year, price decreased by -86.43%.
CUR Key Statistics
- Market Cap
- 3.192M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.37
- Dividend Yield
- N/A
CUR Stock Performance
CUR Stock Chart
CUR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CUR. When comparing the yearly performance of all stocks, CUR is a bad performer in the overall market: 97.87% of all stocks are doing better.
CUR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CUR. CUR may be in some trouble as it scores bad on both profitability and health.
CUR Earnings
CUR Forecast & Estimates
CUR Financial Highlights
Over the last trailing twelve months CUR reported a non-GAAP Earnings per Share(EPS) of -5.37. The EPS decreased by -858.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -43516.23% | ||
| ROA | -190.29% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CUR Ownership
About CUR
Company Profile
NEURALSTEM's patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company expects that its first Investigational New Drug application will be for the treatment of Ischemic Paraplegia, a form of paraplegia that sometimes results from the surgery to repair aortic aneurysms and for which there is no effective treatment.
Company Info
NEURALSTEM INC
20271 Goldenrod Lane
Germantown MD 20876
CEO: Kenneth Carter
Phone: 301-366-4841
NEURALSTEM INC / CUR FAQ
What does CUR do?
NEURALSTEM's patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company expects that its first Investigational New Drug application will be for the treatment of Ischemic Paraplegia, a form of paraplegia that sometimes results from the surgery to repair aortic aneurysms and for which there is no effective treatment.
Can you provide the latest stock price for NEURALSTEM INC?
The current stock price of CUR is 1.52 null. The price decreased by -16.94% in the last trading session.
Does NEURALSTEM INC pay dividends?
CUR does not pay a dividend.
What is the ChartMill rating of NEURALSTEM INC stock?
CUR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of NEURALSTEM INC (CUR) based on its PE ratio?
NEURALSTEM INC (CUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.37).
What is the market capitalization of CUR stock?
NEURALSTEM INC (CUR) has a market capitalization of 3.19M null. This makes CUR a Nano Cap stock.